(E/Z) -BCI

CAT: 0804-HY-126390Size: 1 mgDry Ice: NoHazardous: No
CAT#:0804-HY-126390Size:1 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
(E/Z) -BCI (NSC 150117) is a dual-specificity phosphatase 6 (DUSP6) inhibitor with anti-inflammatory activities. (E/Z) -BCI attenuates LPS-induced inflammatory mediators and ROS production in macrophage cells via activating the Nrf2 signaling axis and inhibiting the NF-κB pathway[1].
CAS Number
[15982-84-0]
Product Name Alternative
NSC 150117
UNSPSC
12352005
Hazard Statement
H302-H315-H319-H412
Target
Apoptosis; Phosphatase
Type
Reference compound
Related Pathways
Apoptosis; Metabolic Enzyme/Protease
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/e-z-bci.html
Solubility
10 mM in DMSO
Smiles
O=C1/C(C(NC2CCCCC2)C3=C1C=CC=C3)=C\C4=CC=CC=C4
Molecular Formula
C22H23NO
Molecular Weight
317.42
Precautions
P264-P270-P273-P280-P302+P352-P305+P351+P338-P330-P362+P364-P501
References & Citations
[1]Zhang F, et al. DUSP6 Inhibitor (E/Z) -BCI Hydrochloride Attenuates Lipopolysaccharide-Induced Inflammatory Responses in Murine Macrophage Cells via Activating the Nrf2 Signaling Axis and Inhibiting the NF-κB Pathway. Inflammation. 2019 Apr;42 (2) :672-681.|[2]Wu QN, et al. Pharmacological inhibition of DUSP6 suppresses gastric cancer growth and metastasis and overcomes cisplatin resistance. Cancer Lett. 2018 Jan 1;412:243-255.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Popular Products